NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Overview Fund Activity
Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

21 hedge funds and large institutions have $301K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
21
Holders Change
-6
Holders Change %
-22.22%
% of All Funds
0.33%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
4
Reduced
3
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
TSS
1
Two Sigma Securities
New York
$10.7K
2
Geode Capital Management
2
Geode Capital Management
Massachusetts
$13.5K
3
Wells Fargo
3
Wells Fargo
California
$56
4
Morgan Stanley
4
Morgan Stanley
New York
$8

Top Sellers

1
AC
1
Armistice Capital
New York
$0
2
DCMIC
2
Decheng Capital Management III (Cayman)
Cayman Islands
$0
3
Renaissance Technologies
3
Renaissance Technologies
New York
$0
4
CM
4
CM Management
Florida
$0
5
KAS
5
Kestra Advisory Services
Texas
$15.6K
Name Holding Trade Value Shares
Change 		Shares
Change %
UBS Group
26
UBS Group
Switzerland
– -$127 -68 Closed
1
2